Skip to main content
. 2021 Mar 24;8(11):2004856. doi: 10.1002/advs.202004856

Figure 6.

Figure 6

A) Monitoring of on‐chip A549 spheroid penetration of 100 × 10−6 m, 10 × 10−6 m, and 1 × 10−6 m doxorubicin (DOX) over a cultivation period of 4 h, n = 6 ± SD. B) Dose‐response relationships of CIS and DOX treated A549 spheroids of different sizes (generated in 1000, 900, 700, 500, and 300 µm microwells) in the spheroid array chip for 24 h using a dye exclusion assay (Hoechst; cell nuclei and ethidium homodimer‐1; dead cells), n = 4–6 ± SD. Statistical analysis of respective CIS and DOX concentrations was performed using the mixed‐effects model. (*p < 0.0332, **p < 0.0021, ***p < 0.0002, ****p < 0.0001). C) Combinatorial on‐chip drug screening of CIS and DOX in correlation to untreated controls after 24 h exposure of A549 spheroids of various dimensions, n = 3–6 ± SD. Corresponding fluorescent micrographs of treated different‐sized A549 spheroids of CIS:DOX for 24 h to screen drug toxicity by staining cell nuclei (Hoechst; blue) and dead cells (Ethidium homodimer‐1; red). Scale bar, 1 mm.